Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Lanuza PM"'
Autor:
Philippon C; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Tao S; Department of Biomedical Informatics, and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.; Blood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, Zhejiang, China., Clement D; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Haroun-Izquierdo A; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden., Kichula KM; Department of Biomedical Informatics, and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO., Netskar H; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Brandt L; Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Oei VS; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Kanaya M; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Lanuza PM; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden., Schaffer M; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden., Goodridge JP; Fate Therapeutics Inc, San Diego, CA., Horowitz A; Department of Oncological Sciences, The Marc and Jennifer Lipshultz Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Zhu F; Blood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, Zhejiang, China., Hammer Q; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden., Sohlberg E; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden., Majhi RK; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway., Kveberg L; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Önfelt B; Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Norman PJ; Department of Biomedical Informatics, and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO., Malmberg KJ; Precision Immunotherapy Alliance (PRIMA), Institute for Clinical medicine, The University of Oslo, Oslo, Norway.; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Publikováno v:
Blood advances [Blood Adv] 2023 Aug 22; Vol. 7 (16), pp. 4492-4504.
Autor:
Haroun-Izquierdo A; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Lanuza PM; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Pfefferle A; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Netskar H; Institute for Cancer Research, Department of Cancer Immunology, University of Oslo, Oslo University Hospital, Norway., Ask EH; Institute for Cancer Research, Department of Cancer Immunology, University of Oslo, Oslo University Hospital, Norway., Törlén J; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden., Björklund A; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden., Sohlberg E; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Malmberg KJ; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Institute for Cancer Research, Department of Cancer Immunology, University of Oslo, Oslo University Hospital, Norway. Electronic address: kalle.malmberg@ki.se.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2023 Jun; Vol. 29 (6), pp. 376.e1-376.e11. Date of Electronic Publication: 2023 Mar 25.
Autor:
Pesini C; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Hidalgo S; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatrics and Public Health, ARAID Foundation/University of Zaragoza, Zaragoza, Spain., Arias MA; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatrics and Public Health, ARAID Foundation/University of Zaragoza, Zaragoza, Spain.; CIBER Enfermedades Infecciosas, Madrid, Spain., Santiago L; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatrics and Public Health, ARAID Foundation/University of Zaragoza, Zaragoza, Spain.; CIBER Enfermedades Infecciosas, Madrid, Spain., Calvo C; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Medical Oncopediatry Department, Aragón Health Research Institute (IIS Aragón), Hospital Universitario Miguel Servet, Zaragoza, Spain., Ocariz-Díez M; Medical Oncology Department, Aragón Health Research Institute (IIS Aragón), Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain., Isla D; Medical Oncology Department, Aragón Health Research Institute (IIS Aragón), Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain., Lanuza PM; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Agustín MJ; Pharmacy Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Galvez EM; CSIC, Instituto de Carboquimica (ICB), Zaragoza, Spain., Ramírez-Labrada A; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Unidad de Nanotoxicología e Inmunotoxicología (UNATI), Biomedical Research Center of Aragón (CIBA), Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain., Pardo J; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatrics and Public Health, ARAID Foundation/University of Zaragoza, Zaragoza, Spain.; CIBER Enfermedades Infecciosas, Madrid, Spain.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2022 Jul 06; Vol. 11 (1), pp. 2096359. Date of Electronic Publication: 2022 Jul 06 (Print Publication: 2022).
Autor:
Lanuza PM; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Alonso MH; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain., Hidalgo S; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatry and Public Health, University of Zaragoza, Zaragoza, Spain., Uranga-Murillo I; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatry and Public Health, University of Zaragoza, Zaragoza, Spain.; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., García-Mulero S; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain., Arnau R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Sanjuan X; Department of Pathology, University Hospital Bellvitge (HUB-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Santiago L; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Oncology and Pharmacology Units, HUMSICB-CSIC, Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Comas L; Oncology and Pharmacology Units, HUMSICB-CSIC, Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Redrado S; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Oncology and Pharmacology Units, HUMSICB-CSIC, Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Pazo-Cid R; Hospital Universitario Miguel Servet, Zaragoza, Spain., Agustin-Ferrández MJ; Hospital Universitario Miguel Servet, Zaragoza, Spain., Jaime-Sánchez P; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Pesini C; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Gálvez EM; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Oncology and Pharmacology Units, HUMSICB-CSIC, Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Ramírez-Labrada A; Unidad de Nanotoxicología e Inmunotoxicología (UNATI), Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Arias M; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatry and Public Health, University of Zaragoza, Zaragoza, Spain.; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain.; ARAID Foundation, Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain., Pardo J; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Microbiology, Radiology, Pediatry and Public Health, University of Zaragoza, Zaragoza, Spain.; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; ARAID Foundation, Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Jun 07; Vol. 13, pp. 890836. Date of Electronic Publication: 2022 Jun 07 (Print Publication: 2022).
Autor:
Santiago L; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Castro M; Department of Pharmacology and Physiology, Faculty of Health and Sports Sciences, University of Zaragoza, 22002 Huesca, Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain., Garzón M; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Ramirez-Labrada A; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Tapia E; Animal Unit, University of Zaragoza, 50009 Zaragoza, Spain., Moreno V; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain., Layunta E; Department of Pharmacology and Physiology, Faculty of Veterinary, University of Zaragoza, 50013 Zaragoza, Spain., Gil-Gómez G; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona., Garrido M; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona., Peña R; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), 08003 Barcelona., Lanuza PM; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Comas L; Instituto de Carboquímica ICB-CSIC, 50018 Zaragoza, Spain., Jaime-Sanchez P; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Uranga-Murillo I; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain., Del Campo R; Department of Microbiology, University Hospital Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain., Pelegrín P; Unidad de Inflamación Molecular y Cirugía Experimental, Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Camerer E; Université de Paris, Paris Cardiovascular Research Center, INSERM U970, 75015 Paris, France., Martínez-Lostao L; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain; Department of Immunology, University Clinic Hospital Lozano Blesa, 50009, Zaragoza, Spain and Department of Pathology, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, 50009 Zaragoza, Spain; Nanoscience Institute of Aragon (INA), University of Zaragoza, 50018 Zaragoza, Spain; Department Biochemistry and Molecular and Cell Biology and Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain., Muñoz G; Department of Immunology, University Clinic Hospital Lozano Blesa, 50009, Zaragoza, Spain and Department of Pathology, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, 50009 Zaragoza, Spain., Uranga JA; Department of Basis Health Sciences, Faculty of Health Sciences, Rey Juan Carlos University, 28922 Madrid, Spain., Alcalde A; Department of Pharmacology and Physiology, Faculty of Veterinary, University of Zaragoza, 50013 Zaragoza, Spain., Galvez EM; Instituto de Carboquímica ICB-CSIC, 50018 Zaragoza, Spain., Ferrandez A; Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain., Bird PI; Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University 3800 Melbourne, Australia., Metkar S; XEME Biopharma Inc., Lombard, IL, USA., Arias MA; Instituto de Carboquímica ICB-CSIC, 50018 Zaragoza, Spain. Electronic address: maykelariascabrero@gmail.com., Pardo J; Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragon (CIBA), 50009 Zaragoza, Spain; Aragon I+D Foundation (ARAID), Zaragoza, Spain; Nanoscience Institute of Aragon (INA), University of Zaragoza, 50018 Zaragoza, Spain; Department Biochemistry and Molecular and Cell Biology and Department Microbiology, Preventive Medicine and Public Health, University of Zaragoza, 50009 Zaragoza, Spain; CIBER-BBN, Madrid, Spain. Electronic address: pardojim@unizar.es.
Publikováno v:
Cell reports [Cell Rep] 2020 Jul 07; Vol. 32 (1), pp. 107847.
Autor:
Lanuza PM; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Pesini C; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain., Arias MA; Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Calvo C; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Medical Oncopediatry Department, Aragón Health Research Institute (IIS Aragón), Hospital Universitario Miguel Servet, Zaragoza, Spain., Ramirez-Labrada A; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Unidad de Nanotoxicología e Inmunotoxicología (UNATI), Centro de Investigación Biomédica de Aragón (CIBA), Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain., Pardo J; Immunotherapy, Inflammation and Cancer, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Aragón i + D Foundation (ARAID), Government of Aragon, Zaragoza, Spain.; Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain.; Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2020 Jan 09; Vol. 10, pp. 3010. Date of Electronic Publication: 2020 Jan 09 (Print Publication: 2019).
Autor:
Lanuza PM; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain., Vigueras A; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Group of Applied Mechanics and Bioengineering (AMB); Instituto de Investigación en Ingeniería de Aragón (I3A), Universidad de Zaragoza, Spain.; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN)., Olivan S; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Group of Applied Mechanics and Bioengineering (AMB); Instituto de Investigación en Ingeniería de Aragón (I3A), Universidad de Zaragoza, Spain.; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN)., Prats AC; Inserm, U1037, F-31432 Toulouse, France, Université de Toulouse, UPS, Cancer Research Center of Toulouse, F-31432 Toulouse, France., Costas S; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain., Llamazares G; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Group of Applied Mechanics and Bioengineering (AMB); Instituto de Investigación en Ingeniería de Aragón (I3A), Universidad de Zaragoza, Spain.; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN)., Sanchez-Martinez D; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain., Ayuso JM; Medical Engineering, Morgridge Institute for Research, Madison, Wisconsin, USA.; Department of Biomedical Engineering, Wisconsin Institutes for Medical Research, University of Wisconsin, Madison, WI, USA.; The University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, USA., Fernandez L; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Group of Applied Mechanics and Bioengineering (AMB); Instituto de Investigación en Ingeniería de Aragón (I3A), Universidad de Zaragoza, Spain.; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN)., Ochoa I; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Group of Applied Mechanics and Bioengineering (AMB); Instituto de Investigación en Ingeniería de Aragón (I3A), Universidad de Zaragoza, Spain.; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN)., Pardo J; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.; Dpt. Microbiology, Preventive Medicine and Public Health and Dpt. Biochemistry and Molecular and Cell Biology, University of Zaragoza, Zaragoza, Spain.; Aragón I+D Foundation (ARAID), Government of Aragon, Zaragoza, Spain Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2018 Feb 12; Vol. 7 (4), pp. e1395123. Date of Electronic Publication: 2018 Feb 12 (Print Publication: 2018).
Autor:
Núñez D; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain.; Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Comas L; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain.; Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Lanuza PM; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain., Sánchez-Martinez D; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain., Pérez-Hernández M; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain., Catalán E; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain., Domingo MP; Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain., Velázquez-Campoy A; Department of Biochemistry and Molecular and Cell Biology, Fac. Ciencias, University of Zaragoza, Zaragoza, Spain.; Institute of Biocomputation and Physics of Complex Systems (BIFI), Unidad Asociada IQFR-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, Spain.; Aragón I + D Foundation (ARAID), Government of Aragon, Zaragoza, Spain., Pardo J; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Aragón I + D Foundation (ARAID), Government of Aragon, Zaragoza, Spain.; Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain.; Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain., Gálvez EM; Immune Effector Cells Group, Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2017 Dec 21; Vol. 8, pp. 1817. Date of Electronic Publication: 2017 Dec 21 (Print Publication: 2017).
Autor:
Claveria-Gimeno R; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain.; Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, 50009, Spain.; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain., Lanuza PM; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain.; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain.; Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza, 50009, Spain., Morales-Chueca I; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain.; Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, 50009, Spain., Jorge-Torres OC; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, 08908, Spain., Vega S; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain., Abian O; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain.; Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, 50009, Spain.; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain.; Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza, 50009, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain., Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, 08908, Spain.; Department of Physiological Sciences II, School of Medicine, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, 08010, Spain., Velazquez-Campoy A; Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain.; Aragon Institute for Health Research (IIS Aragon), Zaragoza, 50009, Spain.; Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza, Zaragoza, 50009, Spain.; Fundacion ARAID, Government of Aragon, Zaragoza, 50018, Spain.
Publikováno v:
Scientific reports [Sci Rep] 2017 Jan 31; Vol. 7, pp. 41635. Date of Electronic Publication: 2017 Jan 31.
Autor:
Ayuso JM; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain., Virumbrales-Muñoz M; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain., Lacueva A; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain., Lanuza PM; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Dpt. Biochemistry and Molecular and Cell Biology, University of Zaragoza, Zaragoza, Spain., Checa-Chavarria E; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Bioengineering Institute, University Miguel Hernández, Spain., Botella P; Instituto de Tecnología Química (Universitat Politècnica de Valencia-Consejo Superior de Investigaciones Científicas), Spain., Fernández E; Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Bioengineering Institute, University Miguel Hernández, Spain., Doblare M; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain., Allison SJ; Department of Biology, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, United Kingdom., Phillips RM; Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, United Kingdom., Pardo J; Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.; Dpt. Biochemistry and Molecular and Cell Biology, University of Zaragoza, Zaragoza, Spain.; Dpt. Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain.; Aragón I+D Foundation (ARAID), Government of Aragon, Zaragoza, Spain., Fernandez LJ; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain., Ochoa I; Group of Structural Mechanics and Materials Modelling (GEMM), Centro Investigacion Biomedica en Red. Bioingenieria, biomateriales y nanomedicina (CIBER-BBN), Spain.; Aragón Institute of Engineering Research (I3A), University of Zaragoza, Spain.; Aragon Institute of Biomedical Research, Instituto de Salud Carlos III, Spain.
Publikováno v:
Scientific reports [Sci Rep] 2016 Oct 31; Vol. 6, pp. 36086. Date of Electronic Publication: 2016 Oct 31.